BiotechTube

CA-4948

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes, Anemia

Trial Timeline

Jan 1, 2022 → Jul 31, 2024

NCT ID
NCT05178342

About CA-4948

CA-4948 is a phase 2 stage product being developed by Curis for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT05178342. Target conditions include Myelodysplastic Syndromes, Anemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05178342Phase 2Terminated

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
decitabine + azacitidineEisaiApproved
85
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
Subcutaneous DecitabineEisaiPhase 1
33
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
DecitabineJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52

Other Products from Curis

chondrocyte-alginate gel suspensionPhase 3
69
Emavusertib + ZanubrutinibPhase 2
44
CUDC-907Phase 2
44
Emavusertib + IbrutinibPhase 1/2
33
Emavusertib + Venetoclax + EmavusertibPhase 1/2
33